MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 886 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JNK-IN-21
CAS:<p>JNK-IN-21 (Compound 62) is an inhibitor of JNK-1.</p>Fórmula:C19H16N2O2SCor e Forma:SolidPeso molecular:336.408KRAS G12C inhibitor 15
CAS:<p>KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor .</p>Fórmula:C25H21ClF2N4O3Pureza:98%Cor e Forma:SolidPeso molecular:498.91CK1δ-IN-9
CAS:<p>CK1δ-IN-9 (Compound 8) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ with an IC50 of 1.4 nM. The compound also inhibits p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 exhibits favorable pharmacokinetic properties, including high oral bioavailability (70%) and moderate clearance.</p>Fórmula:C16H12FN5Cor e Forma:SolidPeso molecular:293.298p38-α MAPK-IN-10
CAS:<p>p38-α MAPK-IN-10 (Compound 6) is an inhibitor of p38α, with an IC50 value of 4 nM.</p>Fórmula:C27H34Cl2N6Cor e Forma:SolidPeso molecular:513.505p38-α MAPK-IN-9
CAS:<p>p38-α MAPK-IN-9 (Compound 25a) is a p38-α MAPK inhibitor with a Ki value of 0.057 nM. It effectively inhibits LPS-induced TNFα production in hPBMC cells, exhibiting an IC50 of 18 nM.</p>Fórmula:C19H20N8O2Cor e Forma:SolidPeso molecular:392.414Casein kinase 1δ-IN-31
CAS:<p>Casein kinase1δ-IN-31 (Compound 16) is an inhibitor of casein kinase (CK), specifically targeting CK1α, CK1δ, and p38α, with IC50 values of 196 nM, 17 nM, and 18 nM, respectively. Additionally, Casein kinase1δ-IN-31 inhibits Double Homeobox 4 (DUX4) with an IC50 of 1200 nM.</p>Fórmula:C17H13FN4Cor e Forma:SolidPeso molecular:292.31pan-KRAS-IN-17
CAS:<p>pan-KRAS-IN-17 (Example 34) is an inhibitor that targets multiple forms of the KRAS protein.</p>Fórmula:C34H33F3N5O8PCor e Forma:SolidPeso molecular:727.623AM-001
CAS:AM-001 is a non-competitive inhibitor of Epac1, preventing the activation of its downstream effector Rap1 in cultured cells. This compound is utilized in research related to cardiac diseases.Fórmula:C24H16FN3OS2Cor e Forma:SolidPeso molecular:445.53J-104871
CAS:<p>J-104871 (UNII-6137X5QNJF) is an FTase inhibitor that inhibits tumor growth in nude mice transplanted with activated H-ras-transformed NIH3T3 cells.</p>Fórmula:C38H32N2O12Pureza:98%Cor e Forma:SolidPeso molecular:708.67KRAS inhibitor-37
CAS:<p>KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.</p>Fórmula:C32H33ClFN7O3Cor e Forma:SolidPeso molecular:618.10KRAS G12C inhibitor 20
CAS:<p>KRAS G12C inhibitor 20 is a KRAS G12C inhibitor.</p>Fórmula:C33H37ClFN7O3Cor e Forma:SolidPeso molecular:634.14KRAS G12C inhibitor 56
CAS:<p>KRAS G12C inhibitor 56, a powerful inhibitor of SOS1 with an inhibitory concentration (IC50) of 1.6 nM, holds promise for use in cancer research.</p>Fórmula:C32H39N7O4SCor e Forma:SolidPeso molecular:617.76p38α MAPK/CK1δ inhibitor-1
CAS:<p>p38αMAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.185 µM and 0.089 µM, respectively.</p>Fórmula:C24H17FN6O2Cor e Forma:SolidPeso molecular:440.429EBI-1051
CAS:<p>EBI-1051 is a highly potent and orally efficacious inhibitor of MEK (IC50: 3.9 nM).</p>Fórmula:C18H15F2IN2O5Pureza:98%Cor e Forma:SolidPeso molecular:504.22G-479
CAS:<p>G-479, a potent MEK inhibitor and improved analogue of GDC-0623, has distributed polarity enhancing bioactivity.</p>Fórmula:C16H15FIN5O4Cor e Forma:SolidPeso molecular:487.22NHTD
CAS:<p>NHTD, a KRAS-PDEδ inhibitor, exerts its function by targeting the isoprenyl binding pocket of PDEδ, which alters the cellular localization of KRAS. This modification restricts the proliferation of cancer cells with KRAS mutations and induces cell apoptosis (Apoptosis). NHTD is utilized in the study of KRAS-driven non-small cell lung cancer (NSCLC).</p>Fórmula:C24H26N2O5Cor e Forma:SolidPeso molecular:422.47SOS2 ligand 1
CAS:<p>SOS2 ligand 1 (compound 2) is a selective ligand for son of sevenless 2 (SOS2), exhibiting a KD value of 4.6 µM.</p>Fórmula:C19H21N5OCor e Forma:SolidPeso molecular:335.403Brimarafenib
CAS:<p>Brimarafenib is a selective RAF dimerization inhibitor, which can inhibit BRAF and CRAF, and exhibits inhibitory effects on a variety of RAF mutations.</p>Fórmula:C24H17F3N4O4Pureza:98.32%Cor e Forma:SolidPeso molecular:482.41KRAS G12D inhibitor 16
CAS:<p>KRAS G12D inhibitor 16 targets KRAS G12D with IC50 of 0.7 nM and mutant form at 0.35 μM, useful in various cancer studies.</p>Fórmula:C32H39IN6O3Cor e Forma:SolidPeso molecular:682.59pan-KRAS degrader 1
CAS:<p>Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.</p>Fórmula:C22H26N8OSCor e Forma:SolidPeso molecular:450.56
